BC Extra | Aug 12, 2019
Company News

Aug. 12 Company Quick Takes: Jazz buying Cavion; plus Boehringer, AC Immune, Oncologie

Jazz gains essential tremor asset via Cavion takeout   Jazz Pharmaceuticals plc (NASDAQ:JAZZ) acquired Cavion Inc. for $52.5 million up front and up to $260 million in clinical, regulatory and sales milestones in a deal...
BioCentury | Jun 10, 2019
Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

Oncologie's strategy of pairing in-licensed, later-stage compounds with biomarkers led Nan Fung Life Sciences and Pivotal bioVenture Partners China to return to invest in the cancer company's tranched $80 million series B. The funds are...
BC Week In Review | Jun 8, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie...
BC Extra | Jun 7, 2018
Financial News

Oncologie raises $16.5M for dual U.S.-China strategy

Cancer company Oncologie Ltd. (Cayman Islands) raised $16.5 million in a seed financing led by Pivotal bioVenture Partners China. Nan Fung Life Sciences, China Merchant Bank Investments and Volcanics Ventures also joined the round. Oncologie...
BC Week In Review | Feb 16, 2018
Company News

Oncologie purchases bavituximab from Avid

Oncologie Ltd. (Cayman Islands) acquired a phosphatidylserine-targeting program including bavituximab from Avid Bioservices Inc. (NASDAQ:CDMO), formerly Peregrine Pharmaceuticals. Avid, which transitioned to a contract development and manufacturing organization in January, will receive $8 million upfront...
BC Innovations | Apr 21, 2017
Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
BC Week In Review | Oct 17, 2016
Clinical News

Bavituximab: Interim Phase III data

Interim data from the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC showed that once-weekly IV bavituximab plus docetaxel missed the primary endpoint of improving median...
BC Week In Review | Mar 7, 2016
Clinical News

Bavituximab: Phase III discontinued

Peregrine discontinued the double-blind, international Phase III SUNRISE trial in about 582 previously treated patients with stage IIIb/IV non-squamous NSCLC after a pre-specified interim analysis by an IDMC showed that once-weekly IV bavituximab plus docetaxel...
BC Week In Review | Nov 16, 2015
Company News

Peregrine, AstraZeneca deal

The companies expanded an August deal and will evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab in an international Phase II trial in patients with previously treated squamous or non-squamous non-small cell lung cancer (NSCLC). The original...
BC Week In Review | Oct 5, 2015
Company News

Peregrine, AstraZeneca deal

The companies partnered to evaluate Peregrine’s bavituximab with AstraZeneca’s durvalumab ( MEDI4736 ) to treat multiple solid tumors. Peregrine will conduct a Phase I/Ib trial. Bavituximab, a chimeric mAb against phosphatidylserine , is in Phase III testing for...
Items per page:
1 - 10 of 120